Adverse events after imatinib mesylate therapy.
Elliott
Michelle A
MA
Mesa
Ruben A
RA
Tefferi
Ayalew
A
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015477:Leukemia, Myelomonocytic, Chronic / Q000188:drug therapy; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D055728:Primary Myelofibrosis / Q000188:drug therapy; D011743:Pyrimidines / Q000009:adverse effects*; D011859:Radiography; D013161:Splenic Rupture / Q000139:chemically induced* / Q000000981:diagnostic imaging; D013163:Splenomegaly / Q000139:chemically induced / Q000000981:diagnostic imaging
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate